Other

OCI Cash Flow Hedge Gain (Loss), After Tax, Parent

Vertex Pharmaceuticals OCI Cash Flow Hedge Gain (Loss), After Tax, Parent decreased by 117.4% to -$9.40M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 154.3%, from $17.30M to -$9.40M.

Analysis

StatementIncome Statement
SectionOther
CategoryRisk
SignalContext dependent
VolatilityVolatile
First reportedQ1 2017
Last reportedQ3 2025

How to read this metric

Fluctuations reflect the effectiveness of the company's hedging strategy and the underlying market volatility of the hedged items.

Detailed definition

The net impact of cash flow hedging activities on comprehensive income after accounting for tax effects and reclassifica...

Peer comparison

Standard reporting for companies utilizing derivative instruments to manage financial risk.

Metric ID: is_tmusz_oci_cash_flow_hedge_gain_loss_after_tax_parent

Historical Data

8 periods
 Q1 '23Q2 '23Q3 '23Q4 '23Q2 '24Q3 '24Q2 '25Q3 '25
Value$3.50M$3.50M$3.50M$3.50M-$3.20M$17.30M$54.10M-$9.40M
QoQ Change+0.0%+0.0%+0.0%-191.4%+640.6%+212.7%-117.4%
YoY Change-191.4%+394.3%>999%-154.3%
Range-$9.40M$54.10M
CAGR+75.9%
Avg YoY Growth+459.8%
Median YoY Growth+120.0%

Frequently Asked Questions

What is Vertex Pharmaceuticals's oci cash flow hedge gain (loss), after tax, parent?
Vertex Pharmaceuticals (VRTX) reported oci cash flow hedge gain (loss), after tax, parent of -$9.40M in Q3 2025.
How has Vertex Pharmaceuticals's oci cash flow hedge gain (loss), after tax, parent changed year-over-year?
Vertex Pharmaceuticals's oci cash flow hedge gain (loss), after tax, parent decreased by 154.3% year-over-year, from $17.30M to -$9.40M.
What does oci cash flow hedge gain (loss), after tax, parent mean?
The after-tax gain or loss from hedging activities that is recorded outside of net income.

Cookie Preferences

We use cookies for analytics. See our Privacy and Cookie Policy.